Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our market websites.
-
RELVAR™ ELLIPTA™ receives positive opinion from the CHMP in Europe for the treatment of asthma and COPD
GSK and Theravance, Inc. today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommend...
Read more -
GSK receives Priority Review from FDA for dabrafenib/trametinib combination in metastatic melanoma
GSK today announced that the US Food and Drug Administration (FDA) has granted Priority Review designation to its supplemental New Drug Applications (sNDAs) for combined use of ...
Read more -
GSK statement in response to patent ruling reversal on Lovaza
GSK confirmed today that the Court of Appeals for the Federal Circuit has ruled against Pronova Biopharma Norge AS in its patent litigation regarding Lovaza® (omega-3-acid ethyl...
Read more -
FDA grants GSK and Genmab’s Arzerra® (ofatumumab) Breakthrough Therapy designation for previously untreated chronic lymphocytic leukaemia
GSK and Genmab A/S announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for Arzerra® (ofatumumab) in combination with chlo...
Read more -
ViiV Healthcare Presents Positive Data from Phase IIIb/IV Study of Dolutegravir vs Darunavir in Treatment-Naïve Adults with HIV-1
ViiV Healthcare today announced initial results from the Phase IIIb/IV FLAMINGO (ING114915) study.
Read more -
FDA Advisory Committee recommends approval in US of umeclidinium/vilanterol for the treatment of COPD
GSK and Theravance, Inc. today announced that the Pulmonary-Allergy Drugs Advisory Committee (PADAC) to the US Food and Drug Administration (FDA) voted 11 yes to 2 no that the e...
Read more -
GSK reaches agreement to divest Lucozade and Ribena for £1.35 billion
GSK today announced it has reached agreement to sell its nutritional drinks brands Lucozade and Ribena to Suntory Beverage & Food Ltd.
Read more -
The investigational MAGE-A3 antigen-specific cancer immunotherapeutic does not meet first co-primary endpoint in Phase III melanoma clinical trial
In line with the Independent Data Monitoring Committee's (IDMC) unanimous recommendation, GSK will continue the DERMA trial until the second co-primary endpoint is assessed.
Read more -
GSK receives marketing authorisation from the European Commission for Tafinlar™
GSK announced today that the European Commission has granted marketing authorisation for Tafinlar™ (dabrafenib).
Read more -
GSK announces phase III study of vercirnon in patients with moderate-to-severe Crohn’s disease did not meet its primary endpoint
GSK announced that the first of four Phase III studies, the SHIELD-1 study, investigating vercirnon - an investigational CCR9 antagonist - in adult patients with moderately-to-s...
Read more -
GSK receives marketing authorisation from the European Commission for additional indication: Tyverb™ (lapatinib)
GlaxoSmithKline announced today that the European Commission has granted an additional indication for Tyverb™ (lapatinib) to be used in combination with trastuzumab.
Read more -
ViiV Healthcare announces U.S. approval of Tivicay® (dolutegravir) for the treatment of HIV-1
ViiV Healthcare is pleased to announce today that the U.S. Food and Drug Administration (FDA) has approved Tivicay® (dolutegravir) 50-mg tablets.
Read more -
GSK launches 50 million venture capital fund to invest in pioneering bioelectronic medicines and technologies
GSK today announced the launch of Action Potential Venture Capital Limited, a new $50 million strategic venture capital fund that will invest in companies that pioneer bioelectr...
Read more -
Regulatory Update - GSK announces EU submission seeking additional indication for Votrient® as maintenance therapy for advanced ovarian cancer
GSK today announced submission to the European Medicines Agency of a variation to the Marketing Authorisation for Votrient® (pazopanib)
Read more -
Regulatory update – GSK announces EU submission for Cervarix® two dose schedule
GSK today announced the submission of a regulatory application in the European Union for a two dosing schedule in 9-14 year old girls for its cervical cancer vaccine.
Read more -
Regulatory update: albiglutide US PDUFA date extended by three months
GSK today announced that the US Prescription Drug User Fee Act (PDUFA) goal date for albiglutide, an investigational once-weekly treatment for adult patients with type 2 diabete...
Read more -
GSK adds to its commitment to GAVI Alliance to help protect millions more children against infectious diseases
New extension of Synflorix vaccine supply agreement will help protect an additional 80 million children in the world’s poorest countries from pneumococcal disease.
Read more -
GSK receives positive CHMP opinion for REVOLADE in thrombocytopenia associated with chronic hepatitis C infection
GSK announced a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorisation for Revolade™ (e...
Read more -
Results announcement for the second quarter 2013
GSK announces Q2 core EPS growth of 4% and dividend of 18p
Read more -
GSK statement regarding recent meeting with Chinese authorities
Following a meeting with the Chinese Ministry of Public Security to discuss their investigation into GSK, Abbas Hussain, President International - Europe, Japan, Emerging Market...
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose to improve the quality of human life.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday healthcare products to medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines & consumer healthcare from inside and outside our labs. Go #BehindTheScience to see for yourself
